Articles On Biotron (ASX:BIT)

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

ASX rises on rally across the board Israel and Hezbollah agree to 60-day ceasefire City Chic tumbles after downbeat update   The Aussie share market enjoyed a solid ride on Wednesday, driven by a broad rally as optimism from Wall Street’s...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

ASX closes flat amid shift from banks to miners CPI slows to 2.7pc, first dip within RBA’s target Fortescue shares soar 6pc on electric truck upgrade   The ASX closed 0.19% lower on Wednesday as the shift from financial stocks to miners...

Biotron (ASX:BIT) has angered shareholders on HotCopper as the results of its latest COVID-treating drug trial come up dusty. “There were no statistically significant differences between drug and placebo groups based on change in SARS-C...

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, which is meant to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

ASX 200 punches it, record highs back in view  11 of 11 sectors higher, like a well-oiled machine  Great day for small caps, goldies and Augustus Minerals Local markets surged this morning after yet another record-breaking night for Wa...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

Biotron (ASX:BIT) has announced that preliminary data analyses from the BIT225-011 Phase 2 clinical trial of its lead antiviral drug BIT225 indicate that the primary objectives have been met.

ASX closes lower, but Energy sector blinks green Uranium mining stocks surged on Peter Dutton’s nuclear plans VanEck to launch Australia’s first Bitcoin ETF tomorrow    Local shares closed Wednesday -0.1% lower as gains in Energy were of...

Biotron jumps after Phase 2 trial success Biotron (ASX:BIT) jumped +15% this morning after announcing promising results from its BIT225-011 Phase 2 clinical trial, indicating that the primary objectives of the study have been achieved. This...

Shares in otherwise thinly traded healthcare microcap Biotron Limited (ASX:BIT) jumped 14.6% to 5.5cps on Wednesday following the release of Phase 2 HIV trial results using BIT225-011. Notable also in today’s share price move is a massiv...

Biotron (ASX: BIT) has received further indications that its lead antiviral drug BIT225 is a potential candidate for the treatment of issues related to HIV. The company has informed shareholders that preliminary analyses of data from a Phas...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

Biotron has announced preliminary analyses of data from the BIT225-010 Phase 2 clinical trial of its lead antiviral drug BIT225.

05 Apr 2024 - A snapshot of the stocks on the move, featuring Linius Technologies Ltd (ASX:LNU), Biotron Limited (ASX:BIT) and Elixir Energy (ASX:EXR).

Biotron (ASX: BIT) has obtained promising early results from a phase 2 clinical trial of the company’s lead antiviral drug BIT225. Preliminary analysis of trial data indicates BIT225 is having a unique effect beyond that seen with the curre...

  To register for today's webinar click here. Linius Technologies Ltd (ASX:LNU) has signed a second US college conference and its first deployment in American football. The agreement is to provide its Whizzard sports solution to the Lone St...

The market may be falling today, but that hasn't stopped Biotron Ltd (ASX: BIT) shares from rocketing. In morning trade, the ASX healthcare stock is up almost 50% to 11 cents. Why is this ASX healthcare stock rocketing? Investors have been...

The ASX 200 slipped by -0.3% on Tuesday, tracking movements on Wall Street overnight.  The local market was dragged down by profit taking in the Tech and Comm Services sectors, while Energy was the only one to close in the green. Advancers...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

  Local markets end +0.13% higher in quasi-comeback Consumer Staples soar on bumper Coles news, but offset by everyone else Small Caps led by Audeara on the back of a massive manufacturing sale   The indignation of Coles has led Consumer...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, that made announcements today. The telecommu...

We’ve all heard that “trend is your friend.” And who doesn’t like riding a trend? Trend or momentum trading involves buying a stock that has shown a significant movement in price or volume. Momentum traders believe that these trends will co...

The S&P ASX 200 fell -3.8% in October with mid-caps falling -6.94% and small-caps down -5.45% for the month S&P ASX 200 Energy was the only sector that closed October in the black with all Australian equity factors in red Dimerix...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

Momentum trading involves taking advantage of, and making profits from, upward trends in a stock. There’s a bit of risk involved in momentum trading because in essence, you’re making a decision to buy a stock based on recent buying activiti...

The Week That Was The world looks very different this week after the addition of what Barclays economic team calls ‘a complex cocktail of geopolitical risk, mixed macro data, a nervous oil market,’ and a US Fed finding nice things to say ab...

Benchmark index finishes Friday ahead +0.4% Sectors led by Financials Small caps dominated by Dimerix   The ASX200 is up +0.4% at  the end of Friday trade, making the week a 1% loss, which we’ll take at this stage. US equities ticked l...

Benchmark index falls to 11-month lows Utilities only sector in green Small caps led by Noxopharm   Local markets have extended unexpected October losses on Wednesday as tech stocks, and the Financial Sector led losses on another bond-...

Benchmark index falls on Monday, closing out the day down 0.21% Utilities and Materials sectors edge higher, but Health Care anchors the benchmark into the red Small caps led by Galileo Mining, Infinity and last week’s rockstar Biotron...

Aussie Futures lower, but shares likely to show reilience RBA cash rate decision to be the main focus  Markets expect central bank to hold rates steady at 4.1 per cent on Tuesday   Futures for the benchmark ASX200 are trading 38 points l...

We look at which ASX stocks are trading on a momentum 52-week high and RSI are two indicators of momentum Simple Moving Average is also another measure of momentum   Last week, we looked at how traders find stocks that are trading with mo...

The Economic Week That Was As I return to the fold on a blistering Sunday arvo in Sydenham, my steel-toed boot into the midriff of American politics is out and the following tribute to breakmanship US style is in: At about 9pm on Saturday n...

This week’s Bulls N’ Bears profiled ASX runner is … Pioneer Resources. It jumped 95 per cent to join other impressive runners including MetalsTech, Biotron and Haranga Resources.

Benchmark index, up +0.34%, ends month on a positive after dropping -1.5% in September Materials Sector out front after strong run for iron ore, uranium prices Small caps led by, BIO, CXO and CZR   Local markets, led almost single-handedl...

Stockhead’s Top 10 at shortly-before-11-ish, produced in a tearing rush because it’s the Friday before a long weekend in the middle of the school holidays so of course everyone’s got ‘the flu’, or their grandma has died for the third time t...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

Benchmark index settles almost -0.6% lower on Tuesday All sectors bar Healthcare and Financials in the red Small caps led by NickelSearch and Biotron A positive lead from Wall Street overnight didn’t sell well on local markets, which were...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...